Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

NCT00574379 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

805

Enrollment

INDUSTRY

Sponsor class

Conditions

Seasonal Allergic Rhinitis
Hay Fever
Allergic Conjunctivitis
Hypersensitivity

Interventions

DRUG: Bilastine
DRUG: Placebo

Sponsor

Faes Farma, S.A.

Collaborators

[object Object]
[object Object]